Last reviewed · How we verify
Analgesic effect of topical tetracaine 2 %
Analgesic effect of topical tetracaine 2 % is a Small molecule drug developed by Rambam Health Care Campus. It is currently in Phase 1 development.
At a glance
| Generic name | Analgesic effect of topical tetracaine 2 % |
|---|---|
| Sponsor | Rambam Health Care Campus |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Analgesic effect of topical tetracaine 2 % CI brief — competitive landscape report
- Analgesic effect of topical tetracaine 2 % updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI
Frequently asked questions about Analgesic effect of topical tetracaine 2 %
What is Analgesic effect of topical tetracaine 2 %?
Analgesic effect of topical tetracaine 2 % is a Small molecule drug developed by Rambam Health Care Campus.
Who makes Analgesic effect of topical tetracaine 2 %?
Analgesic effect of topical tetracaine 2 % is developed by Rambam Health Care Campus (see full Rambam Health Care Campus pipeline at /company/rambam-health-care-campus).
What development phase is Analgesic effect of topical tetracaine 2 % in?
Analgesic effect of topical tetracaine 2 % is in Phase 1.